Alexander O. Schuth

CIK: 0001724311

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (64.3%)

Position reduction

Option Exercises (M)3 (21.4%)

Derivative conversions

Awards (A)2 (14.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DNLI

Denali Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

DNLI
Denali Therapeutics Inc.
Sep 1, 2026
Sale(S)
Direct
2.8K shares at avg. $23.44$65K
DNLI
Denali Therapeutics Inc.
Aug 11, 2026
Sale(S)
Direct
2.9K shares at avg. $25.07$72K
DNLI
Denali Therapeutics Inc.
Jan 6, 2026
Sale(S)
Direct
17.2K shares at avg. $16.50$284K
DNLI
Denali Therapeutics Inc.
Jan 3, 2026
Award(A)
Direct
57.7K shares-
DNLI
Denali Therapeutics Inc.
Aug 12, 2025
Sale(S)
Direct
2.9K shares at avg. $13.58$40K
DNLI
Denali Therapeutics Inc.
Jan 7, 2025
Sale(S)
Direct
2.9K shares at avg. $20.81$60K
DNLI
Denali Therapeutics Inc.
Jan 6, 2025
Sale(S)
Direct
12.3K shares at avg. $20.22$248K
DNLI
Denali Therapeutics Inc.
Jan 3, 2025
Award(A)
Direct
54.2K shares-
DNLI
Denali Therapeutics Inc.
Dec 27, 2024
Exercise(M)
Direct
6.7K shares at avg. $5.28$35K
DNLI
Denali Therapeutics Inc.
Nov 22, 2024
Exercise(M)
Direct
20.5K shares at avg. $0.68$14K
DNLI
Denali Therapeutics Inc.
Nov 7, 2024
Sale(S)
Direct
300 shares at avg. $31.29$9K
DNLI
Denali Therapeutics Inc.
Nov 7, 2024
Sale(S)
Direct
2.9K shares at avg. $30.72$90K
DNLI
Denali Therapeutics Inc.
Nov 7, 2024
Sale(S)
Direct
12.3K shares at avg. $29.68$366K
DNLI
Denali Therapeutics Inc.
Nov 7, 2024
Exercise(M)
Direct
15.6K shares at avg. $5.28$82K

		Type	Shares	Price		Ownership
Sep 1, 2026	DNLI Denali Therapeutics Inc.	Sale(S)	2,768	$23.44	$64,882	Direct
Aug 11, 2026	DNLI Denali Therapeutics Inc.	Sale(S)	2,857	$25.07	$71,625	Direct
Jan 6, 2026	DNLI Denali Therapeutics Inc.	Sale(S)	17,218	$16.50	$284,097	Direct
Jan 3, 2026	DNLI Denali Therapeutics Inc.	Award(A)	57,700	-	$0	Direct
Aug 12, 2025	DNLI Denali Therapeutics Inc.	Sale(S)	2,937	$13.58	$39,884	Direct
Jan 7, 2025	DNLI Denali Therapeutics Inc.	Sale(S)	2,907	$20.81	$60,495	Direct
Jan 6, 2025	DNLI Denali Therapeutics Inc.	Sale(S)	12,255	$20.22	$247,796	Direct
Jan 3, 2025	DNLI Denali Therapeutics Inc.	Award(A)	54,180	-	$0	Direct
Dec 27, 2024	DNLI Denali Therapeutics Inc.	Exercise(M)	6,708	$5.28	$35,418	Direct
Nov 22, 2024	DNLI Denali Therapeutics Inc.	Exercise(M)	20,516	$0.68	$13,951	Direct
Nov 7, 2024	DNLI Denali Therapeutics Inc.	Sale(S)	300	$31.29	$9,387	Direct
Nov 7, 2024	DNLI Denali Therapeutics Inc.	Sale(S)	2,925	$30.72	$89,856	Direct
Nov 7, 2024	DNLI Denali Therapeutics Inc.	Sale(S)	12,333	$29.68	$366,043	Direct
Nov 7, 2024	DNLI Denali Therapeutics Inc.	Exercise(M)	15,558	$5.28	$82,146	Direct

1-14 of 14 transactions

About Schuth Alexander O.

Schuth Alexander O. (SEC CIK 0001724311) files insider reports with the SEC as COFO and Secretary of Denali Therapeutics Inc. (DNLI).

Signal8 holds 10 ownership filings by Schuth Alexander O., all Form 4s, filed between Nov 12, 2024 and Sep 3, 2026. Those filings report 14 transactions, from Nov 7, 2024 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Schuth Alexander O.'s filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Schuth Alexander O.

Sep 1, 2026: Open-market sale of DNLI shares (Form 4, code S).
Aug 11, 2026: Open-market sale of DNLI shares (Form 4, code S).
Jan 6, 2026: Open-market sale of DNLI shares (Form 4, code S).
Jan 3, 2026: Grant or award of DNLI shares (Form 4, code A).
Aug 12, 2025: Open-market sale of DNLI shares (Form 4, code S).

Other insiders filing for Denali Therapeutics Inc. (DNLI)

Chin Peter Scott, Chief Medical Officer
Thornberry Nancy, Director
Watts Ryan J., President and CEO
FLATLEY JAY T, Director
Klein Peter S, Director
Krognes Steve E., Director

How to read Form 4 transaction codes